INT201952

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2006
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 11
Total Number 14
Disease Relevance 8.81
Pain Relevance 2.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (DPP4) extracellular region (DPP4) cell adhesion (DPP4)
Golgi apparatus (DPP4) endoplasmic reticulum (DPP4) plasma membrane (DPP4)
Anatomy Link Frequency
fibroblasts 3
capillary 1
mesenchymal cells 1
DPP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 18 100.00 Very High Very High Very High
rheumatoid arthritis 113 99.84 Very High Very High Very High
Inflammation 87 98.52 Very High Very High Very High
chemokine 151 98.48 Very High Very High Very High
cytokine 136 98.00 Very High Very High Very High
Arthritis 220 80.48 Quite High
spinal inflammation 95 71.28 Quite High
antagonist 15 60.64 Quite High
beta blocker 1 57.60 Quite High
Calcium channel 1 56.40 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 113 99.84 Very High Very High Very High
Skin Cancer 4 99.72 Very High Very High Very High
Pancreatitis 83 99.32 Very High Very High Very High
Systemic Lupus Erythematosus 2 98.84 Very High Very High Very High
Cancer 267 98.60 Very High Very High Very High
INFLAMMATION 91 98.52 Very High Very High Very High
Carcinoma 12 98.24 Very High Very High Very High
Renal Cancer 156 96.52 Very High Very High Very High
Arthropathy 15 95.20 Very High Very High Very High
Autoimmune Disease 5 94.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, there may be two main mechanisms by which DPP IV affects cellular function: on one hand its catalytic activity on bioactive peptides and, on the other hand, its direct interaction with certain molecules located outside the cells [9,26,36].
DPP IV Binding (interaction) of
1) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.98 Pain Relevance 0
Statistical analyses of grading for cell surface DPP IV (DPP IV/CD26) and staging for both soluble and membrane-bound DPP IV activities were not significant.
CD26 Spec (analyses) Binding (grading) of
2) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.41 Pain Relevance 0
DPP IV is a glycoprotein which presents demonstrated pleiotropic effects, and it is likely that this multifunction accounts for its varied roles in different cancers.
DPP IV Spec (likely) Binding (accounts) of associated with cancer
3) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 1.02 Pain Relevance 0
Statistical analyses of grading for cell surface DPP IV (DPP IV/CD26) and staging for both soluble and membrane-bound DPP IV activities were not significant.
DPP IV Spec (analyses) Binding (grading) of
4) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.41 Pain Relevance 0
Hypersialylated DPP IV has been recognized in rheumatoid arthritis and systemic lupus erythematosus [45].
DPP IV Binding (recognized) of associated with rheumatoid arthritis and systemic lupus erythematosus
5) Confidence 0.33 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.68 Pain Relevance 0.25
The guidelines specifically recommend DPP-4 inhibitors as monotherapy for patients with HbA1c levels between 6.5% and 7.5%, as part of 2-drug combination therapy with metformin in patients with HbA1c levels between 7.6% and 9.0%, and as part of triple combination therapy (eg, with metformin and a TZD) for patients with HbA1c > 9.0%.1 The guidelines also note that these agents have low risk for hypoglycemia and no long-term toxicities to date.1
DPP-4 Binding (recommend) of associated with hypoglycemia
6) Confidence 0.29 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.27 Pain Relevance 0
Saxagliptin is a potent, reversible, competitive DPP-4 inhibitor that selectively inhibits DPP-4.16 This is in contrast to its effects on other DPP enzymes, including DPP-8 and DPP-9.16 Based on calculated binding affinities to DPP-4, saxagliptin is 10-fold more potent than either sitagliptin or vildagliptin, although this does not translate clinically.16,21,26 Saxagliptin exhibits prolonged binding to the DPP-4 active site, which results in an extended inhibition of this enzyme.16,26
DPP-4 Binding (affinities) of
7) Confidence 0.29 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.22 Pain Relevance 0.04
did not significantly affect membrane-bound activity of DPP IV on fibroblasts (Figure 10b,c).
DPP IV Binding (bound) of in fibroblasts
8) Confidence 0.28 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.35 Pain Relevance 0.21
Also, capillary endothelial cells possessed membrane-bound CD26/DPP IV (data not shown).
CD26/DPP IV Binding (bound) of in capillary
9) Confidence 0.28 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.98 Pain Relevance 0.58
Together with the expression of CXCL10, the expression of membrane-bound CD26/dipeptidyl peptidase IV was also upregulated in fibroblasts by IFN-?
peptidase IV Binding (bound) of in fibroblasts
10) Confidence 0.28 Published 2006 Journal Arthritis Res Ther Section Abstract Doc Link PMC1779382 Disease Relevance 1.05 Pain Relevance 0.71
Together with the expression of CXCL10, the expression of membrane-bound CD26/dipeptidyl peptidase IV was also upregulated in fibroblasts by IFN-?
CD26 Binding (bound) of in fibroblasts
11) Confidence 0.28 Published 2006 Journal Arthritis Res Ther Section Abstract Doc Link PMC1779382 Disease Relevance 0.98 Pain Relevance 0.68
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies

Leukocyte infiltration during acute and chronic inflammation is regulated by exogenous and endogenous factors, including cytokines, chemokines and proteases.

CD26 Binding (interaction) of in mesenchymal cells associated with chemokine, inflammation, arthropathy and cytokine
12) Confidence 0.27 Published 2006 Journal Arthritis Res Ther Section Title Doc Link PMC1779382 Disease Relevance 0.54 Pain Relevance 0.39
As noted above, native GLP-1 is rapidly metabolized by DPP-IV, which is widely expressed and can be found in multiple tissues and cell types, as well as in the circulation [5].
DPP-IV Binding (found) of
13) Confidence 0.19 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2997321 Disease Relevance 0.49 Pain Relevance 0
In the context of the heightened interest regarding the association of GLP-1 receptor agonists and DPP-4 inhibitors with pancreatitis, a search of the AERS and SRS databases for reports of pancreatitis observed with other classes of AHAs was conducted by the authors, using data from 1968 through the third quarter of 2008.
DPP-4 Binding (association) of associated with pancreatitis and agonist
14) Confidence 0.14 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2904489 Disease Relevance 0.42 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox